Cargando…
Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants
Emerging SARS-CoV-2 Omicron subvariants continue to disrupt COVID-19 vaccine efficacy through multiple immune mechanisms including neutralizing antibody evasion. We developed COH04S1, a synthetic modified vaccinia Ankara vector that co-expresses Wuhan-Hu-1-based spike and nucleocapsid antigens. COH0...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018591/ https://www.ncbi.nlm.nih.gov/pubmed/36928589 http://dx.doi.org/10.1038/s41541-023-00640-y |
_version_ | 1784907843081601024 |
---|---|
author | Wussow, Felix Kha, Mindy Kim, Taehyun Ly, Minh Yll-Pico, Marcal Kar, Swagata Lewis, Mark G. Chiuppesi, Flavia Diamond, Don J. |
author_facet | Wussow, Felix Kha, Mindy Kim, Taehyun Ly, Minh Yll-Pico, Marcal Kar, Swagata Lewis, Mark G. Chiuppesi, Flavia Diamond, Don J. |
author_sort | Wussow, Felix |
collection | PubMed |
description | Emerging SARS-CoV-2 Omicron subvariants continue to disrupt COVID-19 vaccine efficacy through multiple immune mechanisms including neutralizing antibody evasion. We developed COH04S1, a synthetic modified vaccinia Ankara vector that co-expresses Wuhan-Hu-1-based spike and nucleocapsid antigens. COH04S1 demonstrated efficacy against ancestral virus and Beta and Delta variants in animal models and was safe and immunogenic in a Phase 1 clinical trial. Here, we report efficacy of COH04S1 and analogous Omicron BA.1- and Beta-specific vaccines to protect Syrian hamsters from Omicron subvariants. Despite eliciting strain-specific antibody responses, all three vaccines protect hamsters from weight loss, lower respiratory tract infection, and lung pathology following challenge with Omicron BA.1 or BA.2.12.1. While the BA.1-specifc vaccine affords consistently improved efficacy compared to COH04S1 to protect against homologous challenge with BA.1, all three vaccines confer similar protection against heterologous challenge with BA.2.12.1. These results demonstrate efficacy of COH04S1 and variant-specific derivatives to confer cross-protective immunity against SARS-CoV-2 Omicron subvariants. |
format | Online Article Text |
id | pubmed-10018591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100185912023-03-16 Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants Wussow, Felix Kha, Mindy Kim, Taehyun Ly, Minh Yll-Pico, Marcal Kar, Swagata Lewis, Mark G. Chiuppesi, Flavia Diamond, Don J. NPJ Vaccines Article Emerging SARS-CoV-2 Omicron subvariants continue to disrupt COVID-19 vaccine efficacy through multiple immune mechanisms including neutralizing antibody evasion. We developed COH04S1, a synthetic modified vaccinia Ankara vector that co-expresses Wuhan-Hu-1-based spike and nucleocapsid antigens. COH04S1 demonstrated efficacy against ancestral virus and Beta and Delta variants in animal models and was safe and immunogenic in a Phase 1 clinical trial. Here, we report efficacy of COH04S1 and analogous Omicron BA.1- and Beta-specific vaccines to protect Syrian hamsters from Omicron subvariants. Despite eliciting strain-specific antibody responses, all three vaccines protect hamsters from weight loss, lower respiratory tract infection, and lung pathology following challenge with Omicron BA.1 or BA.2.12.1. While the BA.1-specifc vaccine affords consistently improved efficacy compared to COH04S1 to protect against homologous challenge with BA.1, all three vaccines confer similar protection against heterologous challenge with BA.2.12.1. These results demonstrate efficacy of COH04S1 and variant-specific derivatives to confer cross-protective immunity against SARS-CoV-2 Omicron subvariants. Nature Publishing Group UK 2023-03-16 /pmc/articles/PMC10018591/ /pubmed/36928589 http://dx.doi.org/10.1038/s41541-023-00640-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Wussow, Felix Kha, Mindy Kim, Taehyun Ly, Minh Yll-Pico, Marcal Kar, Swagata Lewis, Mark G. Chiuppesi, Flavia Diamond, Don J. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants |
title | Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants |
title_full | Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants |
title_fullStr | Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants |
title_full_unstemmed | Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants |
title_short | Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants |
title_sort | synthetic multiantigen mva vaccine coh04s1 and variant-specific derivatives protect syrian hamsters from sars-cov-2 omicron subvariants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018591/ https://www.ncbi.nlm.nih.gov/pubmed/36928589 http://dx.doi.org/10.1038/s41541-023-00640-y |
work_keys_str_mv | AT wussowfelix syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT khamindy syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT kimtaehyun syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT lyminh syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT yllpicomarcal syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT karswagata syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT lewismarkg syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT chiuppesiflavia syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants AT diamonddonj syntheticmultiantigenmvavaccinecoh04s1andvariantspecificderivativesprotectsyrianhamstersfromsarscov2omicronsubvariants |